2m 2m 2m 2m 2m 2m 2m
Grace Therap (GRCE)
NASDAQ
$2.45+$0.004 (+0.16%)
Price as of Jun 03, 2026 7:14 PM EDT- $39.8MMarket Cap
- -14.93%1-Year Change
- BiotechnologyIndustry
Grace Therap (GRCE)
$2.45+$0.004 (+0.16%)
Annual
Quarterly
03/31/2025 | 03/31/2024 | 03/31/2023 | 03/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | N/A N/A | N/A N/A | 100.0M N/A | 0 -100.00% | |
Cost of Revenue | N/A N/A | N/A N/A | N/A N/A | 0 -100.00% | |
Gross Profit | 0 N/A | 0 -100.00% | 100.0M N/A | 0 -100.00% | |
Sales and Marketing Expense | N/A N/A | 252,000 -61.88% | 661,000 +27.61% | 518,000 -54.64% | |
Research and Development Expense | -9.5M +103.10% | -4.7M -53.04% | -10.0M +79.38% | -5.6M +33.21% | |
Depreciation and Amortization Expense | 7,000 -36.36% | 11,000 -91.13% | 124,000 N/A | 0 -100.00% | |
Total Operating Expenses | 7.2M +11.44% | 6.4M -15.52% | 7.6M N/A | 0 -100.00% | |
Operating Profit | -16.7M +29.78% | -12.9M -75.36% | -52.2M +234.56% | -15.6M -5.06% | |
Interest Income | 711,000 -21.95% | 911,000 +270.33% | 246,000 +219.48% | 77,000 -28.04% | |
Interest Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | 711,000 -21.95% | 911,000 +270.33% | 246,000 +219.48% | 77,000 -28.04% | |
Total Nonoperating Income and Expense | 3.9M +313.42% | -1.8M -1,096.20% | 184,000 -96.41% | 5.1M +257.16% | |
Income before Taxes | -12.8M -13.06% | -14.7M -71.74% | -52.0M +396.52% | -10.5M -36.25% | |
Income Taxes | -3.2M +74.62% | -1.8M -80.80% | -9.5M +1,372.53% | -648,000 N/A | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | 1.6M -72.23% | |
Net Income | -9.6M -25.56% | -12.9M -69.71% | -42.4M +332.11% | -9.8M -50.10% | |
Net Income from Continuing Operations Applicable to Common | -12.8M -13.06% | -14.7M -71.74% | -52.0M +396.52% | -10.5M -46.81% | |
Basic EPS and Net Income | -0.79 -41.48% | -1.35 +42.11% | -0.95 +251.85% | -0.27 +58.82% | |
Diluted EPS and Net Income | -0.79 -41.48% | -1.35 +42.11% | -0.95 +251.85% | -0.27 +58.82% | |
Basic Weighted Average Shares | 12.1M +26.85% | 9.5M -78.64% | 44.6M +21.09% | 36.8M -68.94% | |
Diluted Weighted Average Shares | 12.1M +26.85% | 9.5M -78.64% | 44.6M +21.09% | 36.8M -68.94% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 22.1M -3.79% | 23.0M -17.47% | 27.9M -8.12% | 30.3M -40.44% | |
Short-Term Investments | N/A N/A | 0 -100.00% | 15,000 -99.89% | 13.3M +36.09% | |
Cash and Cash Equivalents and Short-Term Investments | 22.1M -3.79% | 23.0M -17.52% | 27.9M -36.12% | 43.7M -28.11% | |
Total Current Assets | 22.7M -5.41% | 24.0M -18.03% | 29.3M -35.67% | 45.5M -27.00% | |
Accumulated Depreciation | 1,000 -99.84% | 608,000 +6.67% | 570,000 N/A | N/A N/A | |
Property and Plant and Equipment and Net | 15,000 -37.50% | 24,000 -76.92% | 104,000 -99.50% | 20.9M N/A | |
Total Long-Term Assets | 0 -100.00% | 24,000 -99.80% | 12.2M -64.30% | 34.2M +249.49% | |
Total Assets | 72.0M -1.78% | 73.3M -7.36% | 79.1M -38.48% | 128.6M +105.93% | |
Income Taxes Payable | 2.3M -58.07% | 5.5M -24.95% | 7.3M -56.50% | 16.9M N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Current Liabilities | 1.9M +14.61% | 1.7M -50.63% | 3.4M +4.63% | 3.3M +106.46% | |
Total Long-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Long-Term Liabilities | 5.8M -62.53% | 15.4M +1.87% | 15.1M -55.55% | 34.0M +551.06% | |
Total Liabilities | 5.4M -53.42% | 11.6M +3.48% | 11.2M -45.12% | 20.4M +199.35% | |
Retained Earnings | -220.7M +4.53% | -211.1M +6.48% | -198.3M +27.23% | -155.8M +6.72% | |
Total Stockholders Equity | 66.6M +7.88% | 61.7M -9.14% | 68.0M -37.24% | 108.3M +94.52% | |
Total Shares Outstanding | 13.7M +45.95% | 9.4M -78.93% | 44.6M N/A | 0 N/A | |
Cash Flow | |||||
Cash from Operating Activities | -14.9M +20.85% | -12.3M -22.50% | -15.9M -7.67% | -17.2M +20.36% | |
Capital Expenditures | 0 -100.00% | 22,000 N/A | N/A N/A | N/A N/A | |
Cash from Investing Activities | 0 -100.00% | 104,000 -99.21% | 13.2M +473.45% | -3.5M -64.27% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 14.0M +90.68% | 7.4M +2,320.72% | 304,000 N/A | 0 -100.00% | |
Financials Ratio | |||||
Gross Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Operating Margin | N/A N/A | N/A N/A | -52.15% N/A | N/A N/A | |
Return on Assets | -13.17% -21.91% | -16.86% -58.71% | -40.85% +297.45% | -10.28% -77.72% | |
Return on Equity | -14.91% -24.78% | -19.82% -58.84% | -48.15% +301.96% | -11.98% -79.10% | |
Revenue Growth | N/A N/A | N/A N/A | N/A N/A | -100.00% N/A | |
Current Ratio | 11.77 -17.46% | 14.26 +66.04% | 8.59 -38.52% | 13.97 -64.64% | |
Cash Ratio | 11.47 -16.05% | 13.66 +67.17% | 8.17 -12.19% | 9.31 -71.15% | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow